Antipsychotic medication adherence: Is there a difference between typical and atypical agents?

American Journal of Psychiatry

Volumn 159, Issue 1, 2002, Pages 103-108

  Dolder, Christian R ^a   Lacro, Jonathan P ^b   Dunn, Laura B ^b   Jeste, Dilip V ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE;

ARTICLE; DATA ANALYSIS; DATA BASE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOSIS; ADULT; AGED; COMPARATIVE STUDY; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; SCHIZOPHRENIA; VETERAN;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; VETERANS;

EID: 0036357801     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.1.103     Document Type: Article

References (38)

1. Fenton WS, Blyler CR, Heinssen RK: Determinants of medication compliance in schizophrenia: empirical and clinical findings. Schizophr Bull 1997; 23:637-651
2. Young JL, Zonana HV, Shepler L: Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14:105-122
3. Weiden PJ, Olfson M: Cost of relapse in schizophrenia. Schizophr Bull 1995; 21:419-429
4. Terkelsen KG, Menikoff A: Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics 1995; 8:199-222
5. Wyatt RJ, Henter I, Leary MC, Taylor E: An economic evaluation of schizophrenia: 1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30:196-205
6. Rice DP: The economic impact of schizophrenia. J Clin Psychiatry 1999; 60:4-6
7. Kane J, Honigfeld G, Singer J, Meltzer H (Clozaril Collaborative Study Group): Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
8. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
9. Tollefson GD, Beasley CM Jr, Tamura RN, Tran PV, Potvin JH: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapineor haloperidol. Am J Psychiatry 1997; 154:1248-1254
10. Small JG, Hirsch SR, Arvanitis LA, Miller BG, Link CG: Quetiapine in patients with schizophrenia: a high- and low-dose double-blind comparison with placebo. Arch Gen Psychiatry 1997; 54:549-557
11. Jeste DV, Lacro JP, Bailey A, Rockwell E, Harris J, Caligiuri MP: Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients. J Am Geriatr Soc 1999; 47:716-719
12. Jeste DV, Rockwell E, Harris MJ, Lohr JB, Lacro J: Conventional vs newer antipsychotics in elderly patients. Am J Geriatr Psychiatry 1999; 7:70-76
13. Marder SR: Facilitating compliance with antipsychotic medication. J Clin Psychiatry 1998; 59:21-25
14. Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J, Henderson W, Charney D: Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol. J Clin Psychiatry 2000; 61:382-386
15. Arana GW: An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 2000; 61:5-11
16. Olfson M, Mechanic D, Hansell S, Boyer CA, Walkup J, Weiden PJ: Predicting medication noncompliance after hospital discharge among patients with schizophrenia. Psychiatr Serv 2000; 51:216-222
17. Cabeza IG, Amador MS, Lopez CA, Chavez MG: Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41:349-355
18. Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA: Measuring adherence to behavioral and medical interventions. Control Clin Trials 2000; 21:188S-194S
19. Steiner JF, Prochazka AV: The assessment of refill compliance using pharmacy records: methods validity, and applications. J Clin Epidemiol 1997; 50:105-116
20. Buchanan RW, Breier A, Kirkpatrick B, Ball P, Carpenter WT Jr: Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998; 155:751-760
21. Buchanan A: A two-year prospective study of treatment compliance in patients with schizophrenia. Psychol Med 1992; 22:787-797
22. Dixon L, Weiden P, Torres M, Lehman A: Assertive community treatment and medication compliance in the homeless mentally ill. Am J Psychiatry 1997; 154:1302-1304
23. Heyscue BE, Levin GM, Merrick JP: Compliance with depot antipsychotic medication by patients attending outpatient clinics. Psychiatr Serv 1998; 49:1232-1234
24. Nageotte C, Sullivan G, Duan N, Camp PL: Medication compliance among the seriously mentally ill in a public mental health system. Soc Psychiatry Psychiatr Epidemiol 1997; 32:49-56
25. Owen RR, Fischer EP, Booth BM, Cuffel BJ: Medication noncompliance and substance abuse among patients with schizophrenia. Psychiatr Serv 1996; 47:853-858
26. Pan PC, Tantam D: Clinical characteristics, health beliefs and compliance with maintenance treatment: a comparison between regular and irregular attenders at a depot clinic. Acta Psychiatr Scand 1989; 79:564-570
27. Agarwal MR, Sharma VK, Kumar K, Lowe D: Non-compliance with treatment in patients suffering from schizophrenia: a study to evaluate possible contributing factors. Int J Soc Psychiatry 1998; 44:92-106
28. Razali MS, Yahya H: Compliance with treatment in schizophrenia: a drug intervention program in a developing country. Acta Psychiatr Scand 1995; 91:331-335
29. Garavan J, Browne S, Gervin M, Lane A, Larkin C, O'Callaghan E: Compliance with neuroleptic medication in outpatients with schizophrenia; relationship to subjective response to neuroleptics; attitudes to medication and insight. Compr Psychiatry 1998; 39:215-219
30. Duncan JC, Rogers R: Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998; 43:1133-1137
31. Smith TE, Hull JW, Goodman M, Hedayat-Harris A, Willson DF, Israel LM, Munich RL: The relative influences of symptoms, insight, and neurocognition on social adjustment in schizophrenia and schizoaffective disorder. J Nerv Ment Dis 1999; 187:102-108
32. Hamilton RA, Briceland LL: Use of prescription-refill records to assess patient compliance. Am J Hosp Pharm 1992; 49:1691-1696
33. Corriss DJ, Smith TE, Hull JW, Lim RW, Pratt SI, Romanelli S: Interactive risk factors for treatment adherence in a chronic psychotic disorders population. Psychiatry Res 1999; 89:269-274
34. Patterson TL, Lacro J, McKibbin CL, Davidson K, Jeste DV: Direct observation of medications management (MMAA): results from a new performance-based test in older outpatients with schizophrenia. J Clin Psychopharmacol (in press)
35. Deyo RA, Inui TS, Sullivan B: Noncompliance with arthritis drugs: magnitude, correlates, and clinical implications. J Rheumatol 1981; 8:931-936
36. Peterson GM, McLean S, Millingen KS: Determinants of patient compliance with anticonvulsant therapy. Epilepsia 1982; 23:607-613
37. Steiner JF, Koepsell TD, Fihn SD, Inui TS: A general method of compliance assessment using centralized pharmacy records. Med Care 1988; 26:814-823
38. Steiner JF, Fihn SD, Blair B, Inui TS: Appropriate reductions in compliance among well-controlled hypertensive patients. J Clin Epidemiol 1991; 44:1361-1371